

Dr. Muhammad Usman Shaikh

Section of Haematology

Department of Pathology and Laboratory Medicine/Oncology

SUMMARY:

Publication	66
Book Chapters	01
Contributions to reports, guidelines, and policy documents:	10

Publications

Year 2023

1. Outcomes of Patients with FLT3 Positive Acute Myeloid Leukaemia; an Experience from a Tertiary Care Hospital in Karachi, Pakistan. Zulfiqar M, Ali N, **Shaikh U**, Jehanzeb H, **Arif S**, Khan ZF, Saeed N and Ansar Z. J Cancer Allied Spec. 2023 Aug 13;9(2):553. DOI: [10.37029/jcas.v9i2.553](https://doi.org/10.37029/jcas.v9i2.553)

Year 2022

2. Bullous Sweet syndrome as a presentation of chronic myelogenous leukaemia. Abbas SW, Shah Z and **Shaikh MU**. BMJ Case Rep. 2022 Dec 1;15(12):e250755. DOI: [10.1136/bcr-2022-250755](https://doi.org/10.1136/bcr-2022-250755).
3. Prognostic implications of MUC1 and XBP1 concordant expression in multiple myeloma: A retrospective study. Rajput S, M Khurram, **Usman M**, et al. 25April 2022. <https://doi.org/10.21203/rs.3.rs-1557743/v1>.

Year 2021

4. Transplant in Aplastic Anemia Using Combined Granulocyte Colony-Stimulating Factor Primed Blood and Bone Marrow Stem Cells: A Retrospective Analysis. Ali N, Butt A, Altaf B, Adil SN, **Usman M**. Transplant Proc. Jan-Feb 2021;53(1):386-390. [doi:10.1016/j.transproceed.2020.06.035](https://doi.org/10.1016/j.transproceed.2020.06.035).
5. Ensuing adequate mixing of blood samples before analysis-A proposed method for verification of satisfactory sample mixing by automated red blood cell count analyzers. Shaikh MS, Ahmed S, **Usman M**, Ali N, Sana N. Int J Lab Hematol. 2021 Jun;43(3):e141-e144. [doi:10.1111/ijlh.13447](https://doi.org/10.1111/ijlh.13447).
6. Safety and Efficacy of Convalescent Plasma Treatment in COVID-19 Patients: Collate Trial. Hasan M, **Usman M**, Malik MJ, Jamil B, Nasir N, Habib K, et al. J Vaccines Vaccin. 2021;12: 448. https://www.researchgate.net/publication/351745455_Safety_and_Efficacy_of_Convalescent_Plasma_Treatment_in_COVID-19_Patients_Collate_Trial.
7. Chronic myeloid leukemia as a second malignancy after successful treatment of acute promyelocytic leukemia- A case report, Hematology transfusion and cell therapy.

Mukhtadir A, **Usman M**. Hematol Transfus Cell Ther. 2021 May 18;S2531-1379(21)00073. [doi:10.1016/j.htct.2021.02.014](https://doi.org/10.1016/j.htct.2021.02.014).

8. Fludarabine- based salvage therapy for refractory/relapsed acute leukemia: A single center Experience. Muqtadir A, **Usman M**, Ali N, Haider MN. Leukemia research reports 15(2021)100235. 2021 Jan 28; 15:100235. [Doi: 10.1016/j.lrr.2021.100235](https://doi.org/10.1016/j.lrr.2021.100235).

Year 2020

9. Ensuing adequate mixing of blood samples before analysis-A proposed method for verification of satisfactory sample mixing by automated red blood cell count analyzers. Shaikh MS, Ahmed S, **Usman M**, et al. Int J Lab Hematol. [DOI: 10.1111/ijlh.13447](https://doi.org/10.1111/ijlh.13447).
10. Improved outcome in early induction deaths in patients with acute promyelocytic leukemia after therapeutic and supportive interventions: a follow up study of seven-years' experience at a tertiary care center. **Usman M**, Ali N. Am J Blood Res. 2020;10(4):82-89. PMID: [PMC7486488](https://pubmed.ncbi.nlm.nih.gov/37486488/).
11. Outcome of aplastic anemia using combined GCSF primed blood and bone marrow stem cells- a retrospective analysis. N Ali, **Usman M** et al. Biol Blood Marrow Transplant. 26(2020) 596-5255. <https://doi.org/10.1016/j.bbmt.2019.12.206>.
12. Transplant in Aplastic Anemia Using Combined Granulocyte Colony-Stimulating Factor Primed Blood and Bone Marrow Stem Cells: A Retrospective Analysis. Ali N, Butt A, Altaf B, Adil SN, **Usman M**. Transplantation Proceedings. 2020 Aug 6; S0041-1345(20)30611-4. [doi: 10.1016/j.transproceed.2020.06.035](https://doi.org/10.1016/j.transproceed.2020.06.035).

Year 2019

13. Outcome of donor and recipient sex match versus mismatch in stem cell transplant procedure. Int Jour of Hem Onc. Ali N, Ullah H, **Usman M** & Adil SN. Int J Hematol Oncol. 2019 Dec 18;8(4):IJH21. [doi: 10.2217/ijh-2019-0006](https://doi.org/10.2217/ijh-2019-0006).
14. LMP1 expression in bone marrow trephines of patients with multiple myeloma confers a survival advantage. Rajput S, Minhas K, Azam I, **Usman M**, Hussain A & Nasiralani E. Leuk Lymphoma. 2019 Aug;60(8):1991-2001. [doi: 10.1080/10428194.2018.1563697](https://doi.org/10.1080/10428194.2018.1563697).

Year 2018

15. Compliance of handwritten transfusion requisition form and improvement after online request - a clinical audit. Nasir N, **Usman M**. Journal of Pakistan Medical Association. 2020 Apr;70(4):694-698. DOI: [10.5455/JPMA.14958](https://doi.org/10.5455/JPMA.14958).

Year 2017

16. Bone marrow harvest procedure: Is age really, just a number? Ali N, **Usman M**, Adil S. Open journal of clinical and medical case reports. 2017 July; 14 (3). <http://jclinmedcasereports.com/articles/OJCMCR-1288.pdf>.

Year 2016

17. A case of pancytopenia and reticulocytopenia with multiple granulomas on bone trephine biopsy. Majeed A, **Usman M**. Annals of clinical Pathology. 2016; 4(3):1073. <https://www.jscimedcentral.com/Pathology/pathology-4-1073.pdf>.
18. Pleural effusion as a manifestation of multiple myeloma, case report. Iqbal N, Tariq MU, **Usman M**, Majid H. British Medical Journal. 2016 Aug 12;2016: bcr2016215433. [doi: 10.1136/bcr-2016-215433](https://doi.org/10.1136/bcr-2016-215433).
19. Frequency of varicella zoster virus infection in allogeneic stem cell transplant patients: case series from a single center. Ali N, **Usman U**, Haji H, Adil SN. Drugs Therapeutic Perspective. 2016. [DOI:10.1007/s40267-015-0264-3](https://doi.org/10.1007/s40267-015-0264-3).
20. Clinico pathological profile of patients with PV, ET and PMF: a tertiary care center experience from southern Pakistan. **Usman M**, Mohammad Usman, Adil SN et al. J Ayub med coll Abbottabad. Apr-Jun 2016;28(2):293-297.

Year 2015

21. Autologous hematopoietic stem cell transplantation; ten years data from a developing country. Ali N, Adil SN, **Usman M**. stem cell translational Medicine. 2015 Aug;4(8):873-7. [doi: 10.5966/sctm.2015-0015](https://doi.org/10.5966/sctm.2015-0015).
22. Response and adverse effects of Nilotinib in Imatinib resistant CML patients: data from a developing country. Hussain S, **Usman M**. Clinical Therapeutics. 2015 Nov 1;37(11):2449-57. [doi:10.1016/j.clinthera.2015.08.026](https://doi.org/10.1016/j.clinthera.2015.08.026).

Year 2014

23. Frequency of chromosomal abnormalities in Pakistani adults with acute lymphoblastic leukemia. Shaikh MS, Adil SN, **Usman M**, Khurshid M. Asia Pacific Journal Cancer review. 2014; 15(21):9495-8. DOI: [10.7314/apjcp.2014.15.21.9495](https://doi.org/10.7314/apjcp.2014.15.21.9495).
24. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies. Zahid MF, Ali N, **Usman M**, Adil SN. International Journal of Hematology- Oncology and Stem Cell Research. 2014 Oct 1;8(4):30-8. PMID: [25774265](https://pubmed.ncbi.nlm.nih.gov/25774265/).

25. Response to Imatinib Mesylate in Patients with Early Chronic Phase Chronic Myeloid Leukemia and Derivative Chromosome 9 Deletion or Clonal Evolution. **Usman M**, Moatter T, Syed N, Ali N, Adil S. Clinical and Experimental Pathology. 2014, 4(3): 166. <https://www.omicsonline.org/open-access/response-to-imatinib-mesylate-in-patients-with-early-chronic-phase-chronic-myeloid-leukemia-and-derivative-chromosome-deletion-or-clonal-evolution-2161-0681.1000166.php?aid=26129>.
26. Blood stream and central line isolates from haematopoietic stem cell transplant recipients data from a developing country. N Ali, Adil S, **Usman M**. Transplant Infectious Disease Jan 3, 2014. <https://onlinelibrary.wiley.com/doi/full/10.1111/tid.12176>.
27. Clinical Characteristics, Outcome and Early Induction in Acute Promyelocytic Leukemia: Five years' experience at a tertiary care center. Karim F, **Usman M**. Singapore Medical Journal. 2014 55 (8): 443-447. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294096/>.
28. Estimating window period blood donations for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus by nucleic acid amplification testing in Southern Pakistan. Moiz M, Moatter T, **Usman M**. Transfusion. 2014 Jun;54(6):1652-9. doi: [10.1111/trf.12521](https://doi.org/10.1111/trf.12521).
29. Chromosomal abnormalities in Primary myelodysplastic syndrome. Rashid A, Khurshid M, **Usman M**. JCPSP. 2014 Sep;24(9):632-5.

Year 2013

30. Frequency and Outcome of Graft versus Host Disease after Stem Cell Transplantation: A Six-Year Experience from a Tertiary Care Center in Pakistan. Ali N, Adil SN, **Usman M**, Masood N. ISRN Hematol. 2013 Jun 27; 2013:232519. doi: [0.1155/2013/232519](https://doi.org/0.1155/2013/232519).

Year 2012

31. Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011. Ali N, Adil SN, **Usman M**, Moosajee M, Masood N. Experimental Hematology Oncology. 2012 May 18;1(1):13. doi: [10.1186/2162-3619-1-13](https://doi.org/10.1186/2162-3619-1-13).

YEAR 2011

32. Retrospective review of 25 cases of Thrombotic Thrombocytopenic Purpura in Pakistan. Khalid S, Moiz B, **Usman M**. Therapeutic Apheresis and Dialysis. 2012 Feb;16(1):97-103. doi: [10.1111/j.1744-9987.2011.00998.x](https://doi.org/10.1111/j.1744-9987.2011.00998.x).
33. BK virus induced late onset Hemorrhagic Cystitis after allogeneic peripheral blood stem cell transplantation. Ali N, **Usman M**, Hasan S. Indian Journal of Hematology and Blood Transfusion. 2011 Sep; 27(3): 177–179. DOI [10.1007/s12288-011-0082-2](https://doi.org/10.1007/s12288-011-0082-2). <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155717/>.

34. Outcome of Adult Patients with Acute Lymphoblastic Leukemia Receiving MRC UK ALL XII Protocol –A Tertiary Care Center Experience. **Usman M**, Ali N. Singapore Medical Journal. 2011 May;52(5):370-4.

YEAR 2010

35. Response of CHOP in Diffuse Large B Cell Lymphoma. A Single Center Experience from Pakistan. Kashif M, **Usman M**. Asia-Pacific Journal of Oncology & Hematology. 2010 Jan; 2(2).
https://www.researchgate.net/publication/268405913_Response_of_CHOP_in_Diffuse_Large_B_Cell_Lymphoma_A_Single_Center_Experience_from_Pakistan.
36. Clinicopathologic spectrum of Waldenström's macroglobulinemia: a single center experience. Sajid R, Hasan S, **Usman U**. Indian Journal of Pathology and Microbiology. Jul-Sep 2010;53(3):490-3. <https://pubmed.ncbi.nlm.nih.gov/20699509/>.
37. Therapeutic outcomes of older patients with Acute Myeloid Leukemia. Sajid R, Adil S, Kamran N, **Usman M**. Saudi Medical Journal. 2010 May;31(5):533-8.
<https://pubmed.ncbi.nlm.nih.gov/20464043/>.
38. Acute transfusion reaction encountered in patients at a tertiary care center. Khalid S, **Usman M**, Khurshid M. Journal of Pakistan Medical Association. 2010 Oct;60(10):832-6. <https://pubmed.ncbi.nlm.nih.gov/21381614/>.
39. Copper sulphate toxicity in a young male complicated by methemoglobinemia, rhabdomyolysis and renal failure. Hasan S, **Usman M**, Ali N, Riaz M. Journal of College of Physicians and Surgeons Pakistan. 2010 Jul;20(7):490-1.
<https://pubmed.ncbi.nlm.nih.gov/20642956/>.

YEAR 2008

40. Additional chromosomal abnormalities in Philadelphia-positive chronic myeloid leukemia. Syed NN, **Usman M**, Adil S, Khurshid M. Hematology Oncology stem cell therapy. 2008; 1(3): 166-170.
41. Post-transplant T-cell type Lymphoproliferative disorder. Zubair A, Ahsan A, **Usman M**, Minhas K. Journal of College of Physicians and Surgeons Pakistan. 2008;17(12); 766-8.
42. A fatal case of gram negative sepsis associated with disseminated strongyloidiasis in an immunocompromised patient. Fasih N, Irfan S, **Usman M**, Beg MA. Journal of Pakistan Medical Association. 2008; 58 (2); 91-92.
43. Platelet aggregation test is a useful diagnostic tool for Glanzmann's thrombasthenia in developing countries. Moiz B, Ali N, **Usman M**. Journal of College of Physicians and Surgeons Pakistan. 2008;18 (2).
44. Response of Imatinib Mesylate in Patients with Gastrointestinal Stromal Cell Tumor. Ladha A, **Usman M**. Journal of Pakistan Medical Association. 2008; 58(12); 696-7.

45. Hematological and non-hematological toxicities of Imatinib mesylate in patients with chronic myeloid leukemia and gastrointestinal stromal cell tumor. Naz N, **Usman M**. Indian Journal of Pharmacology. 2007; 39 (4): 192-195. <https://www.ijp-online.com/article.asp?issn=0253->
46. Pattern of chromosomal abnormalities in adult acute lymphoblastic leukemia. Khalid S, **Usman M**, Khurshid M. Indian Journal of Pathology & Microbiology. 2007; 50 (1): 77-81.
47. Thrombocytosis: Age dependent etiology and analysis of platelet indices for differential diagnosis. **Usman M**, Naz N, Khurshid M. Indian Journal of Pathology and Microbiology. 2007;50 (3): 628-633.
48. Chronic phase chronic myeloid leukemia: Response of Imatinib mesylate and significance of sokal score, age, and disease duration in predicting the hematological and cytogenetic response. **Usman M**, Naz N, Kakepoto G, Adil S, Khurshid M. Journal of Association of Physicians of India. 2007 Feb; 55:103-7.
49. Hemorrhagic manifestations and utility of hematological parameters in dengue fever: a tertiary care center experience at Karachi. Ali N, **Usman M**, Naz N, Khurshid M. Scandinavian Journal of Infectious Diseases. 2007;39(11-12):1025-8. [doi: 10.1080/00365540701411492](https://doi.org/10.1080/00365540701411492).
50. Chronic ITP –analysis of various factors at presentation and their response to second line therapy. Syed NN, Adil SN, Sajid R, **Usman M**, Kakepoto GN, Khurshid M. Journal of Pakistan Medical Association. 2007; 57 (3): 126-129. <https://pubmed.ncbi.nlm.nih.gov/17432016/>.
51. Pathologic features of chronic myeloid leukemia and sokal score at time of presentation. Syed NN, **Usman M**, Khaliq G, Adil S, Khurshid M. J Coll Physicians Surg Pak. 2006 May;16(5):336-9. <https://pubmed.ncbi.nlm.nih.gov/16756777/>.
52. Utility of red cell discriminant function (DF) in screening for trait. Bilwani F, Mohammad M, Khalid S, Hirani M, **Usman M**. Pakistan Journal of Pathology. 2006;17(2): 49-52. <https://www.pakjpath.com/index.php/Pak-J-Pathol/article/view/197>.

YEAR 2007

53. Frequency of irregular red cell Alloantibodies in patients with thalassemia major: a bicenter study. Bilwani F, Adil SN, Kakepoto GN, Hassan F, **Usman M**, Khurshid M. Pakistan Medical Association. 2005 Dec;55(12):563-5.
54. Familial homocystienuria. Bilwani F, Syed N, **Usman M**, Khurshid M. Journal of College of physicians and surgeons Pakistan. 2005; 15(2), 106-107. https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/595/.

55. Frequency of FAB subtypes in Acute Myeloid Leukemia patients at Aga Khan University Hospital Karachi. **Usman M**, Kakepoto GN, Bilwani F, Khurshid M. Journal of Ayub Medical College, Abbottabad. Jan-Mar 2005;17(1):26-9. <https://pubmed.ncbi.nlm.nih.gov/15929522/>.
56. Anaphylactic reaction after intramuscular injection of cyanocobalamin (vitamin B12). Bilwani F, Adil SN, **Usman M**, Khurshid M. Journal of Pakistan Medical Association. 2005;55: 217-219. https://jpma.org.pk/article-details/745?article_id=745.
57. Hairy cell leukemia; clinical presentation and long term follow up after treatment with 2-chlorodeoxyadenosine 2-CDA. Bilwani F, **Usman M**, Adil SN, Kakepoto GN, Khurshid M. Journal of Pakistan Medical Association. 2005 May;55(5):212-3. <https://pubmed.ncbi.nlm.nih.gov/15960289/>.

YEAR 2004

58. Adult acute lymphoblastic leukemia. Adil SN, **Usman M**. Journal of Pakistan Medical Association. 2004 Sept; 54(9): 444. <https://www.jpma.org.pk/past-issue/36>.
59. Increased expression of HLA DR 2 in acquired aplastic anemia and its impact on response to immunosuppressive therapy. **Usman M**, Adil SN, Moatter T, Bilwani F, Arain S, Khurshid M. Journal of Pakistan Medical Association, 2004; 54: 251-53. <https://pubmed.ncbi.nlm.nih.gov/15270183/>.
60. Polycythemia Vera and idiopathic erythrocytosis: Comparison of clinical and laboratory parameters. **Usman M**, Bilwani F, Kakepoto GN, Adil SN, Sajid R, Khurshid M. Journal of Pakistan Medical Association. 2004; 54:249- 51. <https://pubmed.ncbi.nlm.nih.gov/15270182/>.
61. Hematologic and cytogenetic findings in eleven chronic myelogenous leukemia patients treated with imatinib mesylate at a tertiary care hospital. **Usman M**, Kakepoto GN, Adil SN, Sajid R, Arain S, Khurshid M. Journal of Pakistan Medical Association. 2004; 54:17-20. https://ecommons.aku.edu/cgi/viewcontent.cgi?referer=&httpsredir=1&article=1560&context=pakistan_fhs_mc_pathol_microbiol.

YEAR 2003

62. Acquire aplastic anemia and bone marrow transplantation. Adil SN, **Usman M**. Journal of Pakistan Medical Association. 2003; 53: 130.
63. Iron deficiency anemia: Management strategies and controversies. Adil SN, **Usman M**. Journal of Pakistan Medical Association. 2003 Apr;53(4):130. <https://pubmed.ncbi.nlm.nih.gov/12776893/>.

64. Outcome of adult acute lymphoblastic leukemia: a single center experience. **Usman M**, Burney I, Nasim A, Adil SN, Salam A, Siddique T, Khurshid M. Journal of Pakistan Medical Association. 2003 Sep;53(9):384-8. <https://pubmed.ncbi.nlm.nih.gov/14620310/>.
65. Cyclosporin induced fatal rhabdomyolysis in a young patient with aplastic anemia. **Usman M**, Adil SN, Kakepoto GN, Khurshid M. Journal of Pakistan Medical Association. 2003; 53:312. <https://jpma.org.pk/article-details/231>.
66. Fludarabine induced thrombocytopenia in a patient with B cell lymphoproliferative disorder. **Usman M**, Adil SN, Sajid R, Khurshid M. Journal of Pakistan Medical Association, 2003; 53:496-7. <https://jpma.org.pk/article-details/289>.

BOOK CHAPTERS:

1. **2017 Usman M.** How I treat adult ITP? How we manage blood disorders with limited resources, ISBN 978-969-9463-02-0; PRINTED BY Gondal graphics, Published by NIBD PUBLICATIONS, 2017.

CONTRIBUTIONS TO REPORTS, GUIDELINES AND POLICY

DOCUMENTS:

1. **2019** Introduction of Mini CEX as a part of Clinical hematology Residency training initiative.
2. **2019** Introduction of competency based Entrustable Professional Attributes (EPA) in Clinical and Laboratory Hematology residency programs.
3. **2016-2017** Introduction of American Association of Continuous Medical Education (AACME) accredited teaching sessions for Residents and Faculty members of Hematology.
4. **2016-2017** Initiated two new one hourly sessions every week (104 sessions per year) named as “Departmental from Consultation Meeting” in laboratory hematology for residents and faculty and get accredited AACME, one credit hour per session.
5. **2015 to date Clinical Indicators:** Quality improvement Projects, Section of Clinical Hematology, Department of Oncology. Number of patients with screening for left ventricular function before receiving Anthracycline.2013 -2015.Patients without serological screening for Hepatitis B surface antigen and core antibodies before the administration of Inj. Rituximab.
6. **2015** Develop **package for diffuse large B cell Lymphoma**, the commonest in Pakistan and a good number of patients get treatment from AKU. Actively coordinate with different departments such as Pharmacy, Laboratory, Radiology and Finance before final approval.
7. **2014** Develop four pager **initial assessment form for the department of Oncology** after taking feedback from other faculty of oncology department.
8. **2014 Hematopoietic stem cell transplant Manual:** Following the observations of mock JCIA audit which was conducted by Ms Salma Jaffer and Dr Mairaj Shah, I develop fifty two pager manual for the use of faculty members of BMT team, trainee residents and nursing staff. Hard copy as well as soft copy is available in BMT unit and intranet JCIA site, respectively; Details include Indications of transplant Pre transplant workup Protocols of autologous and allogenic transplant Donor related issues Prophylaxis medications

Management of graft versus host disease, veno occlusive disease and Hemorrhagic cystitis etc.

9. **2013-2014 Prepared two clinical Pathways:**
 - a) Autologous Bone Marrow Transplant.
 - b) Allogeneic Bone Marrow Transplant and that include matched sibling, reduced intensity and haplo identical.
10. **2012** Introduces the new PGME and CPSP approved Residency Training Program of CLINICAL HEMATOLOGY in the department of Oncology, Aga Khan University.